Treatment options for vancomycin-resistant enterococcal infections

Drugs

Volumn 62, Issue 3, 2002, Pages 425-441

  Linden, Peter K ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMPICILLIN; AZTREONAM; BACITRACIN; BETA LACTAM DERIVATIVE; CEFTRIAXONE; CHLORAMPHENICOL DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; DALFOPRISTIN; DAPTOMYCIN; DOXYCYCLINE; GENTAMICIN; GLYCOPEPTIDE; LINEZOLID; LIPOPEPTIDE; NITROFURANTOIN; NOVOBIOCIN; ORITAVANCIN; PENICILLIN G; PSEUDOMONIC ACID; QUINUPRISTIN; RAMOPLANIN; RIFAMPICIN; STREPTOMYCIN; SULTAMICILLIN; TEICOPLANIN; TIGECYCLINE; TIGILCYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTHRALGIA; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERIOSTASIS; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GASTROINTESTINAL TOXICITY; GENE MUTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYALGIA; NEUROTOXICITY; NONHUMAN; REVIEW; SUPERINFECTION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANIMALIA; BACTERIA (MICROORGANISMS); ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; POSIBACTERIA;

EID: 0036194239     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262030-00002     Document Type: Review

References (121)

1. The enterococcus: 'Putting the bug in our ears'
2. The life and times of the enterococcus
3. Antimicrobial drug resistance
4. Nosocomial bloodstream infection in United States hospitals: A three-year analysis
5. The National Nosocomial Infection Surveillance (NNIS) system. Nosocomial vancomycin-resistant enterococci in the United States 1989-1995. The first 1000 isolates
6. Surveillance of antimicrobial use in United States hospitals: Project ICARE Phase 2
7. Differences in outcome for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium
8. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: Risk factors for acquisition and mortality
9. Incidence and outcome of infection by vancomycin-resistant Enterococcus following orthotopic liver transplantation
10. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit
11. Vancomycin-resistant enterococcal bacteremia: Natural history and attributable mortality
12. Treatment of vancomycin-resistant Enterococcus faecium infections
13. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium
14. Vancomycin-resistant enterococci
15. Emergence of vancomycin-resistant enterococci in New York City
16. High level resistance to gentamicin in clinical isolates of enterococci
17. Nosocomial infection by gentamicin-resistant Streptococcus faecalis: An epidemiologic study
18. β-Lactamase producing enterococci
19. Increasing resistance to â-lactam antibiotics among clinical isolates of Enterococcus faecium: A 22-year review at one institution
20. Vancomycin-resistant enterococcal infections
21. VanD-type glycopeptide-resistant Enterococcus faecalis BM4339
22. Van E, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405
23. Synergistic killing of vancomycin-resistant enterococci of classes A, B, and C by combinations of vancomycin, penicillin, and gentamicin
24. Inconsistent bactericidal activity of triple-combination therapy with vancomycin, ampicillin, and gentamicin against vancomycin-resistant, highly ampicillin-resistant Enterococcus faecium
25. Bactericidal activities of antibiotics against vancomycin-resistant Enterococcus faecium blood isolates and synergistic activities of combinations
26. In vitro synergy and mechanism of interaction between vancomycin and ciprofloxacin against enterococcal isolates
27. Novel antimicrobial regimens against Enterococcus faecium resistant to ampicillin, vancomycin, and gentamicin
28. Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium
29. Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents
30. Comparison of different β-lactam-glycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly β-lactam-resistant and highly glycopeptide-resistant isolate of Enterococcus faecium
31. Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium
32. Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium
33. Vancomycin-resistant enterococci: Clinical, microbiologic, and epidemiologic features
34. High-dose ampicillin plus streptomycin for treatment of a patient with severe infection due to multi-resistant enterococci
35. Efficacy of teicoplanin for enterococcal infections: 63 Cases and review
36. Successful treatment of meningitis due to multiply resistant Enterococcus faecium with a combination of intrathecal teicoplanin and intravenous antimicrobial agents
37. Selection of glycopeptide-resistant mutants of VanB type Enterococcus faecalis BM4281 in vitro and in experimental endocarditis
38. In vivo development of teicoplanin resistance in a VanB Enterococcus faecalis
39. Influence of oral glycopeptides on the fecal flora of human volunteers: Selection of highly glycopeptide-resistant enterococci
40. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients
41. The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococi: A meta-analysis
42. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections
43. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus
44. Vancomycin-resistant Enterococcus faecium meningitis successfully treated with chloramphenicol
45. Successful use of tetracycline as therapy of an immunocompromised patient with septicaemia caused by a vancomycin-resistant Enterococcus
46. Quinupristin/dalfopristin in neonatal Enterococcus faecium meningitis
47. Utilization of novobiocin and ciprofloxacin for the treatment of serious infection due to vancomycin-resistant Enterocccus faecium
48. Effect of novobiocin-containing antimicrobial regimens on infection and colonization with vancomycin-resistant Enterococcus faecium
49. Bacteriologic efficacy of nitrofurantoin for the treatment of urinary tract infection due to vancomycin-resistant Entercoccus faecium
50. Treatment options for chronic prostatitis due to vancomycin-resistant Enterococcus faecium
51. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium
52. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteremia: Comparison with a control cohort
53. Quinupristin-dalfopristin for infections due to vancomycin-resistant Enterococcus faecium
54. Linezolid in the treatment of vancomycin-resistant Enterococcus: A dose comparative, multicenter phase III trial
55. Clinical efficacy of linezolid for infections caused by vancomycin-resistant enterococci (VRE) in a compassionate use program
56. The streptogramin antibiotics: Update on their mechanism of action
57. RP 59500: A proposed mechanism for its bactericidal activity
58. Quinupristin/dalfopristin antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada
59. Evaluation of in vitro activity of quinpristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates
60. Pharmaco-kinetics of quinupristin-dalfopristin in continuous ambulatory peritoneal dialysis patients
61. Post-antibiotic effect and post-antibiotic sub-MIC effect of quinupristin-dalfopristin against Gram-positive and -negative organisms
62. Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill curve and postantibiotic effect methods
63. In vitro activity of RP 59500, an injectable streptogramin antibiotic, against vancomycin-resistant Gram-positive organisms
64. Comparative in vitro activity of quinupristin/dalfoprostin against Enterococcus spp.
65. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium
66. Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium with quinupristin/dalfopristin
67. Therapy with RP 59500 (quinupristin/dalfopristin) for prosthetic valve endocarditis due to enterococci with VanA/VanB resistance patterns
68. Quinupristin/dalfopristin (RP 59500) therapy for vancomycin-resistant Enterococcus faecium aortic graft infection: Case report
69. Vancomycin-resistant Enterococcus faecium. Shunt infection in an infant: An antibiotic cure
70. Association between quinpristin/dalfopristin resistance in glycopeptide-resistant Enterococcus faecium and the use of additives in animal feed
71. Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy
72. Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin/dalfopristin in combination with other antimicrobial agents
73. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetation
74. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: A synergistic drug combination
75. Characterization of arthralgias/myalgias associated with quinupristin/dalfopristin (Synercid)
76. Arthralgias and myalgias related to quinupristin-dalfopristin administration
77. Liver histopathology in liver transplant recipients with hyperbilirubinemia during quinupristin/dalfolpristin therapy
78. Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: Two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin
79. Antibiotic usage in animals: Impact on bacterial resistance and public health
80. Comparison of glycopeptide-resistant Enterococcus faecium isolates and glycopeptide resistance genes of human and animal origins
81. Isolation of vancomycin-resistant enterococci from supermarket poultry
82. vanA-mediated high-level glycopeptide resistance in Enterococcus faecium from animal husbandry
83. Oxazolidinone antibacterial agents
84. Mechanism of action of oxazolidinones: Effects of linezolid and eperzolid on translation reactions
85. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci
86. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae
87. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperzolid (PNU-100766) versus vancomycin against Staphylococcus aureus, cogulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium
88. The in-vitro activity of linezolid (U-100766) and tentative breakpoints
89. In vitro metabolism of linezolid (PNU-100766): Lack of induction or inhibition of cytochrome P450 enzymes and studies on the mechanism of formation of the major human metabolite, PNU-142586
90. Metabolism and excretion of the oxazolidinone antibiotic linezolid (PNU-100766) following oral administration of {14C} PNU-100766 to healthy volunteers
91. Pharmacokinetics of linezolid in subjects with varying degrees of renal function and on dialysis
92. Linezolid and reversible myelosuppression
93. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin)
94. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin
95. Treatment of vanocmycin-resistant Enterococcus faecium infection in liver recipients with the investigational antimicrobial, linezolid
96. Isolation of a vancomycin-resistant enterococcal strain with reduced susceptibility to linezolid
97. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid
98. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid
99. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens
100. In vitro activities of daptomycin against 2,789 clinical isolates in 11 North American medical centers
101. Daptomycin
102. Daptomycin/LY333328/evernimicin. Session S134
103. Evaluation of the in vitro activity of the glycopeptide antibiotic LY 333328 in comparison with vancomycin and teicoplanin
104. In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study
105. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci
106. New narrow spectrum agents for the treatment of infections caused by gram-positives
107. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates
108. Reduction of Staphylococcus aureus nasal carriage, and infection in dialysis patients
109. Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus
110. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus
111. A semiquantitative analysis of the fecal flora of patients with vancomycin-resistant enterococci: Colonized patients pose an infection control risk
112. Skin colonization with vancomycin-resistant enterococci among hospitalized patients with bacteremia
113. Recurrent vancomycin-resistant Enterococcus faecium bacteremia in a leukemia patients who was persistently colonized with vancomycin-resistant enterococci for two years
114. Enteric eradication of vancomycin-resistant Enterococcus faecium with oral bacitracin
115. Use of bacitracin therapy for infection due to vancomycin-resistant Enterococcus faecium
116. Lack of efficacy of oral bacitracin plus doxycycline for the eradication of stool colonization with vancomycin-resistant Enterococcus faecium
117. Comparison of the target sites and mechanism of action of glycopeptides and lipoglycodepsipeptide antibiotics
118. In vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against gram-positive clinical isolates from cancer patients
119. The safety and efficacy of a novel glycopeptide, ramoplanin, in the decolonization of the gastrointestinal tract of persons colonized with VRE